Back to Business

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook

Business September 8, 2026 at 6:12 PM

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook

Investing.com

Read at Investing.com

More Stories

Jefferies reiterates Buy on MP Materials stock, keeps $85 target

Jefferies reiterates Buy on MP Materials stock, keeps $85 target

🇺🇸 Investing.com 22m ago

Meta launches AI agent that can access other apps to send emails, make payments

Meta launches AI agent that can access other apps to send emails, make payments

🇺🇸 Investing.com 28m ago

Trump administration blasts Ford business deals with Chinese firms

Trump administration blasts Ford business deals with Chinese firms

🇺🇸 Investing.com 28m ago

Your world briefing, in your pocket

AI-curated news from 12 countries and 10 languages — coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play